Mette Skalshøi Kjær

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Philip N. Newsome, Iris Kliers, Laura Østergaard et al. · New England Journal of Medicine · 2025 · 690 citations

Medicine, Pharmacology, Pharmacotherapy +17

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 472 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study

Gro Askgaard, Morten Grønbæk, Mette Skalshøi Kjær et al. · Journal of Hepatology · 2015 · 251 citations

Medicine, Internal Medicine, Epidemiologic Methods +14

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder et al. · Nature Metabolism · 2024 · 229 citations · Full text

Medicine, Nutrition, Nutritional Sciences +17

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Naim Alkhouri, Robert Herring, Heidi Kabler et al. · Journal of Hepatology · 2022 · 209 citations

Medicine, Pharmacology, Pharmacotherapy +16